Pacira BioSciences (PCRX) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

US Manufacturing Index Rises To 43, Highest Since 2020
Business TodayNov 16 02:13 ET
Pacira BioSciences Reports Sustained Pain Relief in Osteoarthritis With Gene Therapy Candidate PCRX-201 in Upcoming ACR Presentation
Quiver QuantitativeNov 14 10:47 ET
Express News | Pacira Biosciences Inc - Phase 1 Trial Shows Safety and Efficacy of Pcrx-201
ReutersNov 14 10:05 ET
Express News | Pacira Biosciences Inc - No Serious Treatment-Emergent Adverse Events Reported
ReutersNov 14 10:05 ET
Express News | Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of Pcrx-201 for Moderate to Severe Osteoarthritis of the Knee
ReutersNov 14 10:05 ET
Pacira BioSciences Insider Lowered Holding By 85% During Last Year
Simply Wall StNov 14 05:30 ET

Comments

Value investorr

Aug 23 11:25

My last point: looking into the future of PCRX.

$Pacira BioSciences (PCRX.US)$ $iShares Russell 2000 ETF (IWM.US)$
Besides all the information that is publicly available and that I’ve posted in my previous two comments. Here’s something to keep in mind for PCRX future if you want to make your decision to buy, hold, or sell:
1. Diversification of product pipeline greatly reduces the risk of further top-line (revenue) erosion even if we assume the worst case scenario for Experal (which itself is ex...

4

Value investorr

Aug 19 10:03

A undervalued keeper

$Pacira BioSciences (PCRX.US)$ I believe whoever saw my last comment om this stock has generated a good return over the past week. I think the opportunity is still not fully capitalized and fundamental reasonings from last time still persist.
Additionally, just look at the imsider activities. Wow, from CEO to multiple directors, they are buying and loading a ton of shares and no one is selling. This is just another signal supports my theory and the share price. From its funda...

Share Your Profit/Loss

1

Mr Long Term

Aug 13 17:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...

12

2

Value investorr

Aug 12 09:29

A golden opportunity

$Pacira BioSciences (PCRX.US)$ Let’s layout their current situation and see if the market has priced it appropriately:
Good news:
1. ASP for Exparel +6% reimbursement from the new law
2. THREE Extra upcoming Patent litigation against eVenus infringement
3. Despite the approval, Truist Securities anticipates that eVenus will not be able to launch its generic product until at least the late 2030s due to ongoing patent litigations which means LIMITED DOWNSIDE to current revenue...

5

1